KalVista Pharmaceuticals KALV shares are trading lower after the FDA notified the company that it has placed a clinical hold on its Phase 2 clinical trial of KVD824.
KalVista Pharmaceuticals' stock has been rising Wednesday, up 0.86% to a price of $19.27. The stock's volume is currently 59.63 thousand, which is roughly 48.44% of its recent 30-day volume average of 123.10 thousand.
The 50-day moving average price of KalVista Pharmaceuticals's stock was $20.55 when this article was published. The stock reached a high of $45.0 and a low of $12.01 in the past 52 weeks.
If you're looking for timely and concise explanations of why a stock is moving, check out Benzinga Pro. Subscribers get ‘Why Is It Moving' alerts as soon as our research team identifies the cause of the price action in a stock. Click here to learn more.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
